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ABSTRACT
Objective: To identify interventions designed to
improve recruitment to randomised controlled trials,
and to quantify their effect on trial participation.
Design: Systematic review.
Data sources: The Cochrane Methodology Review
Group Specialised Register in the Cochrane Library,
MEDLINE, EMBASE, ERIC, Science Citation Index,
Social Sciences Citation Index, C2-SPECTR, the
National Research Register and PubMed. Most
searches were undertaken up to 2010; no language
restrictions were applied.
Study selection: Randomised and quasi-randomised
controlled trials, including those recruiting to
hypothetical studies. Studies on retention strategies,
examining ways to increase questionnaire response or
evaluating the use of incentives for clinicians were
excluded. The study population included any potential
trial participant (eg, patient, clinician and member of
the public), or individual or group of individuals
responsible for trial recruitment (eg, clinicians,
researchers and recruitment sites). Two authors
independently screened identified studies for eligibility.
Results: 45 trials with over 43 000 participants were
included. Some interventions were effective in increasing
recruitment: telephone reminders to non-respondents (risk
ratio (RR) 1.66, 95% CI 1.03 to 2.46; two studies, 1058
participants), use of opt-out rather than opt-in procedures
for contacting potential participants (RR 1.39, 95% CI
1.06 to 1.84; one study, 152 participants) and open
designs where participants know which treatment they are
receiving in the trial (RR 1.22, 95% CI 1.09 to 1.36; two
studies, 4833 participants). However, the effect of many
other strategies is less clear, including the use of video to
provide trial information and interventions aimed at
recruiters.
Conclusions: There are promising strategies for
increasing recruitment to trials, but some methods,
such as open-trial designs and opt-out strategies, must
be considered carefully as their use may also present
methodological or ethical challenges. Questions remain
as to the applicability of results originating from
hypothetical trials, including those relating to the use
of monetary incentives, and there is a clear knowledge
gap with regard to effective strategies aimed at
recruiters.
ARTICLE SUMMARY
Article focus
▪ Despite representing the gold standard in evalu-
ating the effectiveness and safety of healthcare
interventions, many randomised controlled trials
do not meet their recruitment targets.
▪ Poor recruitment can lead to extended study dur-
ation, greater resource usage and findings that
are not as statistically precise as intended; in the
worst case, a trial may be stopped.
▪ A systematic review was carried out to identify
methods used to improve recruitment to rando-
mised controlled trials, and to quantify their
effects on participation.
Key messages
▪ There are promising strategies for increasing
recruitment to trials, most notably telephone
reminders, open-trial designs, opt-out strategies
and financial incentives.
▪ Many trials of recruitment methods involve hypo-
thetical trials, and the applicability of their results
to the real world is still unknown.
▪ There is a clear knowledge gap with regard to effect-
ive strategies aimed at those recruiting to trials.
Strengths and limitations of this study
▪ This Cochrane review utilised a comprehensive
search and appraisal strategy, thereby ensuring
that all relevant evidence was included.
▪ Many of the included studies were small,
increasing the likelihood of their being under-
powered, and resulting in CIs that included the
possibility of substantial benefit.
▪ The interventions evaluated by included studies
varied greatly, making it difficult to pool data for
met-analysis.
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INTRODUCTION
Randomised controlled trials represent the gold stand-
ard in evaluating the effectiveness and safety of health-
care interventions, primarily because they help guard
against selection bias.1 Nonetheless, the recruitment of
clinicians and patients to these studies can be extremely
difﬁcult.2 While there are several possible consequences
of poor recruitment, perhaps the most crucial is the
potential for a trial to be underpowered.3 In such cir-
cumstances, clinically relevant differences may be
reported as statistically non-signiﬁcant, increasing the
chance that an effective intervention will either be aban-
doned before its true value is established, or at the very
least, delayed as further trials or meta-analyses are con-
ducted. Similarly, while poor recruitment can be
addressed by extending the length of a trial, this too can
create delay in the roll-out of a potentially effective inter-
vention, while increasing the cost and workload of the
trial itself.
Several investigations of recruitment have attempted
to quantify the extent of the problem, and while esti-
mates differ, it is clear that many trials do not meet their
recruitment targets.2 4–6 Of those that do, many achieve
them only after extending the length of the trial. A
recent cohort study of 114 multicentre trials, supported
by two of the UK’s largest research funding bodies (the
Medical Research Council and the Health Technology
Assessment Programme), found that less than a third
achieved their original target (n=38; 31%), and more
than half had to be extended (n=65; 53%).2 In a similar
study of 41 trials in the US National Institute of Health
inventory, only 14 (34%) met or exceeded their planned
recruitment, while a quarter (n=10; 24%) failed to
recruit more than half.4 In many cases, trials may have
to close prematurely due to recruitment problems.6
While trialists have used many interventions to
improve recruitment, it has been difﬁcult to predict the
effect of these. The purpose of this review was to quan-
tify the effects of speciﬁc methods used to improve
recruitment of participants to randomised controlled
trials, and where possible, to consider the effect of study
setting on recruitment. Although there have been three
previous systematic reviews on strategies to enhance
recruitment to research, two do not include the most
recent literature,7 8 while the third considers the com-
bined effects of interventions across four strategic areas
rather than the individual effects of speciﬁc interven-
tions.9 Our synthesis builds on and updates an earlier
Cochrane review;8 the protocol and full review are avail-
able from the Cochrane Library.10
METHODS
Criteria for inclusion
Study types and participant
We included randomised and quasi-randomised con-
trolled trials, including those recruiting to hypothetical
studies, that is, where potential participants are asked if
they would take part in a trial if it was run, but where no
trial exists. Studies examining ways to increase question-
naire response rates, evaluating the use of incentives or
disincentives to increase clinicians’ recruitment of
patients or studying strategies to improve retention were
excluded as these are addressed by other Cochrane
Methodology Reviews (CMR).11–13 The study population
included any potential trial participant (eg, patient, clin-
ician and member of the public), or an individual or a
group of individuals responsible for recruiting trial parti-
cipants (eg, clinicians, researchers and recruitment
sites).
Types of intervention
A recruitment intervention was deﬁned as any method
implemented to improve the number of participants
recruited to a randomised controlled trial, whether this
was directed at potential participants, at those respon-
sible for recruiting participants or at trial design or
co-ordination. Interventions used in any study setting
were included.
Outcome measure
The outcome of interest was the proportion of eligible
individuals or centres recruited.
Identification of studies
We searched the CMR Group Specialised Register 2010,
Issue 2, part of The Cochrane Library (http://www.
thecochranelibrary.com), ERIC (Educational Resources
Information Centre), CSA (1966 to April 2010), Science
Citation Index and Social Sciences Citation Index, ISI
Web of Science (1975 to April 2010), National Research
Register (online) (2007, Issue 3), The Campbell
Collaboration Social, Psychological, Education and
Criminological Trials Registry (C2-SPECTR) (up to April
2008), MEDLINE, Ovid (1950 to March week 5 2010)
and EMBASE, Ovid (1980 to 2010 week 14). The UK
Cochrane Centre previously ran a series of searches in
MEDLINE (in 2000) and EMBASE (in 2004) to identify
reports of methodological studies, with the resulting cita-
tions being subsequently entered into CMR. To increase
the efﬁciency of our searches, we therefore restricted
our searches of MEDLINE and EMBASE to records
entered from 2001 and 2005, respectively. We searched
PubMed to retrieve ‘related articles’ for 27 studies
included in the previous version of this review. No lan-
guage restrictions were imposed. A sample search is
given in appendix 1; the complete strategy is available
online from the Cochrane Library.10
Selection of studies
Titles and abstracts of identiﬁed studies were independ-
ently screened for eligibility by two reviewers. Full text
versions of papers not excluded at this stage were
obtained for detailed review. Potentially relevant studies
were then independently assessed by two reviewers to
determine if they met the inclusion criteria. Differences
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of opinion were discussed until a consensus was reached;
the opinion of a third reviewer was sought when
necessary.
Data extraction and assessment of bias
Data extraction of included studies was carried out inde-
pendently by two reviewers (ST with EM, PL or MP)
using a pro-forma speciﬁcally designed for the purpose.
Data were extracted on trial design, study setting, partici-
pants, inclusion and exclusion criteria, interventions
and outcomes evaluated and results. In addition, data
on the method of randomisation, allocation conceal-
ment (adequate, clear and inadequate), blinding (full,
partial and none), adequacy (objective, unclear and
subjective) and reporting of outcome measures and
level of follow-up were collected to allow the risk of bias
in each study to be determined.14 This was independ-
ently assessed by the same two reviewers, and sum-
marised in line with Cochrane guidance (A, low risk; B,
moderate risk and C, high risk).15 Studies at a high risk
of bias were not excluded, but results were interpreted
in light of this.
Data synthesis
Data were processed in accordance with the Cochrane
handbook.15 Trials were grouped according to the type
of intervention evaluated (eg, monetary incentives, alter-
native forms of consent, etc), with intervention group-
ings based on similarities in form and content. Where
available, binary data were combined as risk ratios (RR)
and the associated 95% CIs generated. Cluster rando-
mised controlled trials were included only where there
were sufﬁcient data to allow analyses that adjusted for
clustering. In such a case, an odds ratio (OR) was used
as the summary effect in the meta-analysis, with the
pooled result subsequently being converted to an RR
using the average comparator group risk.
Heterogeneity was explored using the χ2 test, and the
degree of heterogeneity observed (ie, the percentage of
variation across studies due to heterogeneity rather than
to chance) was quantiﬁed with the I2 statistic. Where
there was substantial heterogeneity, we informally investi-
gated possible explanations and summarised data using
a random-effects analysis if appropriate. Subgroup ana-
lyses were planned to explore key factors considered to
be potential causes of heterogeneity, namely (1) trial
design (randomised vs quasi-randomised); (2) conceal-
ment of allocation (adequate vs inadequate or unclear);
(3) study setting (primary vs secondary care; healthcare
vs non-healthcare); (4) study design (open vs blinded;
placebo vs none); (5) target group (clinicians, patients
and researchers) and (6) recruitment to hypothetical
versus real trials. However, there were too few studies
evaluating the same or similar interventions to allow
these analyses to be conducted. Similarly, it was not pos-
sible to explore publication bias.
RESULTS
Description of studies
Search results
The search strategy identiﬁed 16 334 articles, of which
301 appeared to meet the inclusion criteria and were
subject to detailed review (ﬁgure 1). We retrieved the
full text of an additional 10 papers identiﬁed from the
reference lists of previous reviews, and one article pub-
lished out with the search period but which appeared
relevant, giving a total of 312 potentially eligible studies.
Forty-ﬁve papers, targeting more than 43 000 individuals,
were included in the ﬁnal analysis. Nineteen studies eval-
uated recruitment to hypothetical trials (table 1).
Study characteristics
Almost half of the studies were carried out in North
America (n=21; 47%), with the remainder located in
Europe (n=18; 40%) and Australia (n=5; 11%). One
study involved centres in 19 countries worldwide. Studies
were comparatively small in size, involving between 6
and 2561 participants (mean 493; median 79). It was
Figure 1 Flow of studies into
the review.
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Table 1 Summary of included studies
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
Avenell et al
(UK)16
Parallel group Secondary
care
Open trial design comparing vitamin
D, with calcium, with vitamin D and
calcium, with no tablets
Conventional trial
comparing vitamin D,
with calcium, with
vitamin D and
calcium, with
placebo
Patients aged ≥70
attending a
fracture clinic or
orthopaedic ward
134/180 (74.4%) 233/358 (65.1%) A Between-group difference
was statistically significant
(OR 1.56; 95% CI 1.05 to
2.33)
Bentley and
Thacker (USA)17
Factorial University
(multicentre,
n=5)
A: Info on a high-risk trial for a drug
not yet tested on humans, pays
$1800
Not applicable Pharmacy
students
Unclear Not applicable C Assessed willingness to take
part in hypothetical studies
by risk and reward; did not
differentiate recruitment rates
between groups (270
participants); between-group
differences were statistically
significant for both risk level
(p<0.0005) and level of
payment (p=0.015)
B: Info on a high-risk trial for a drug
not yet tested on humans, pays
$800
Unclear
C: Info on a high-risk trial for a drug
not yet tested on humans, pays
$350
Unclear
D: Info on a medium-risk study for a
generic drug already on the market,
pays $1800
Unclear
E: Info on a medium-risk study for a
generic drug already on the market,
pays $800
Unclear
F: Info on a medium-risk study for a
generic drug already on the market,
pays $350
Unclear
G: Info on a low-risk study
measuring the salivary levels of
stress hormones, pays $1800
Unclear
H: Info on a low-risk study
measuring the salivary levels of
stress hormones, pays $800
Unclear
I: Info on a low-risk study measuring
the salivary levels of stress
hormones, pays $350
Unclear
Cooper et al
(UK)18
Parallel group Secondary
care
Partially randomised patient
preference design allocating to
medical management or
transcervical resection of the
endometrium or preferred option
Conventional RCT
design allocating to
medical
management or
transcervical
resection of the
endometrium
First time
attendees at a
gynaecological
clinic
90/135 (96.3%) 97/138 (70.3%) A No information on statistical
significance given
Coyne et al
(USA)19
Cluster Secondary
care
(multicentre,
n=44)
Easy-to-read consent statements
(altered text style, layout, font size,
vocabulary; reading level 7th–8th
grade)
Standard consent
statements
Patients eligible
for participation in
a cancer treatment
trial
75/89 (84.3%) 68/137 (49.6%) C Involved consent statements
for three cancer treatment
trials (one lung, two breast
cancer); actual accrual to the
parent studies was not
significantly different
(p=0.32)
Continued
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
DiGuiseppi et al
(USA)20
Parallel group Health
Maintenance
Organisation
(HMO)
(multicentre)
Telephone administered
questionnaire on hazardous
drinking and willingness to
participate in lifestyle intervention
Face-to-face
administered
questionnaire on
hazardous drinking
and willingness to
participate in lifestyle
intervention
Patients aged ≥18
attending the HMO
with an acute
injury
64/99 (64.6%) 190/370 (51.4%) C Considered different
methods of screening, which
included willingness to
participate in a hypothetical
trial; the telephone group
was somewhat more often
associated with willingness
to participate (OR 1.49; 95%
CI 0.97 to 2.30)
Du et al (USA)21 Parallel group Secondary
care
18 min educational video giving an
overview of clinical trials and the
importance of cancer clinical
research to society
Standard care (ie,
normal first visit to
the oncologist)
Patients aged 21–
80 attending a
multidisciplinary
lung clinic at a
cancer centre
11/63 (17.5%) to
therapeutic trials;
16/63 (25.4%) to
all trials
7/63 (11.1%) to
therapeutic
trials; 10/63
(15.9%) to all
trials
B Considered recruitment to a
range of cancer trials
categorised into
‘therapeutic’, and
‘therapeutic and
non-therapeutic’;
between-group difference
was not statistically
significant for therapeutic
trials (p=0.308) or for all
trials (p=0.187)
Du et al (USA)22 Parallel group Secondary
care
18 min educational video giving an
overview of clinical trials and the
importance of cancer clinical
research to society
Standard care (ie,
normal visit to the
oncologist)
Women aged 21–
80 attending a
breast cancer
clinic at a cancer
centre
10/98 (10.4%) 6/98 (6.1%) C Between-group difference
was not statistically
significant (p=0.277)
Ellis et al
(Australia)23
Parallel group Secondary
care
Information booklet explaining trials,
how treatment is selected in an
RCT, discussion of treatment
options, advantages and
disadvantages of participation,
where to get more info plus usual
discussion about treatment options
from the clinician, inc. RCTs if
appropriate (no standardisation of
what is discussed)
Usual discussion
about treatment
options from the
clinician, inc RCTs if
appropriate (no
standardisation of
what is discussed)
Women
undergoing
definitive surgery
for early stage
breast cancer at a
cancer institute
12/30 (40.0%) at
follow-up
14/30 (46.7%) at
follow-up
C Studied willingness to
participate in a hypothetical
trial; between-group
difference was statistically
significant (p=0.05)
Ford et al (USA)24 Parallel group Community
(multicentre,
n=2)
A: Enhanced recruitment letter,
phone screening by an African
American interviewer, baseline
questionnaire by mail, reminder
calls/mailings for baseline info and
consent
Standard recruitment
letter, phone
screening by an
African American/
Caucasian
interviewer, baseline
questionnaire by
mail, reminder calls/
mailings for return of
baseline info and
consent
African American
men aged 55–74,
eligible for a
prostate, lung and
colorectal cancer
screening trial
78/3079 (2.5%) 95/3297 (2.9%) B Between-group difference
was statistically significant
(p<0.01)
B: Enhanced recruitment letter,
phone screening by an African
American interviewer, baseline
questionnaire by phone, reminder
calls/mailings for consent form
87/3075 (2.8%)
Continued
Trew
eek
S,LockhartP,Pitkethly
M
,etal.BM
J
Open
2013;3:e002360.doi:10.1136/bm
jopen-2012-002360
5
Im
p
ro
v
in
g
re
c
ru
itm
e
n
t
to
R
C
T
s
 
group.bmj.com
 o
n
 August 6, 2013 - Published by 
bmjopen.bmj.com
D
ow
nloaded from
 
Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
C: Enhanced recruitment letter,
phone screening by an African
American interviewer, reminder for
project session held at church,
baseline questionnaire at church
session
116/2949 (3.9%)
Fowell et al (UK)25 Clustered
cross-over
Secondary
care
(multicentre,
n=2)
Cluster randomisation Zelen’s design (only
those randomised to
intervention arm
asked for consent)
Cancer inpatients
receiving palliative
care and starting
on a syringe driver
6/24 (25%) 0/29 (0%) C Considered the effect of trial
design on potential
recruitment rate; aimed to
explore the feasibility of the
two designs for studies of
dying patients;
between-group difference
was statistically significant
(p=0.02)
Free et al (UK)26 Parallel group Community
(multicentre,
n=2)
A: A letter containing study and
consent information, and a £5 note
Normal trial
procedures (letter
and patient
information sheet)
Members of the
public who are
aged ≥16, are
daily smokers and
willing to quit in
the next month
13/246 (5.3%) 1/245 (0.4%) A Evaluated interventions in
separate trials;
between-groups differences
were statistically significant
for both the financial
incentive (OR 4.9; 95% CI
2.0 to 7.7) and text
messages (OR 4.2; 95% CI
2.2 to 6.1)
B: Four text messages over 1 week
containing quotes from existing
participants
Normal trial
procedures (letter
and patient
information sheet)
17/405 (4.2%) 0/406 (0%)
Freer et al (UK)27 Parallel group Tertiary
neonatal
intensive care
unit
A: Five page US version of a study
information leaflet (inc. more detail
on study process, risks, benefits
and patient rights) plus standard
verbal explanation
US version of an
information leaflet
without verbal
explanation
Parents of
immature infant(s)
admitted to the
NICU but not
requiring intensive
care
5/9 (56%) 3/9 (33%) B Considered the impact of
information on parents’
understanding of a research
study and the validity of their
consent to participation in a
hypothetical trial; no
information on statistical
significance given
B: Less detailed single sheet UK
version of a study information leaflet
plus standard verbal explanation
UK version of an
information leaflet
without verbal
explanation
5/9 (56%) 4/10 (40%)
Fureman et al
(USA)28
Parallel group Existing trial
(university
based)
Enhanced video on an HIV vaccine
trial plus a 1 h pamphlet
presentation (5 min pre-test, 26 min
of video, 10 min to review pamphlet,
RA initiated Q&A session, post-test
questionnaire, survey at 1 month
Standard half hour
pamphlet-only
presentation (5 min
pre-test, 10 min to
review a trial info
pamphlet, RA
initiated Q&A
session, post-test
questionnaire, survey
at 1 month
Participants in the
Risk Assessment
Project (injection
drug users)
1.84 (post-test 1);
1.69 (post-test 2)
1.70 (post-test 1);
1.50 (post-test 2)
C Studied recruitment to a
hypothetical trial (targeted
98 individuals for
intervention, 88 for
comparator); results
provided as mean
willingness scores;
between-group difference
was not statistically
significant (p>0.1)
Graham et al
(USA)29
Parallel group Health
Maintenance
Organisation
(multicentre)
A: Electronic questionnaire on
hazardous drinking and willingness
to participate in lifestyle intervention
Standard
self-complete paper
questionnaire
Patients aged ≥18
attending the HMO
with an acute
injury
69/151 (45.7%) 76/141 (53.9%) C Considered different
methods of screening, which
included willingness to
participate in a hypothetical42/78 (53.8%)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
trial; between-group
difference was statistically
significant (p=0.001)
B: Oral questionnaire read aloud to
patients in the clinic, potential
answers printed on cards and
patients asked to point
Halpern et al
(USA)30
Within-subject
design
Secondary
care
A: Variation in trial information on
(1) the percentage of previous
patients experiencing an adverse
effect from the study drug (10%,
20%, 30%) and (2) payment
participants would receive ($100,
$1000, $2000)
Not applicable Patients with mild
to moderate
hypertension
attending an
outpatient clinic
Unclear Not applicable C Assessed willingness to take
part in hypothetical studies
by risk and reward; did not
provide recruitment rates
(126 participants); there was
a statistically significant
increase in willingness to
participate as risk of adverse
effects reduced (p<0.001),
payment level rose
(p<0.001), and the risk of
being assigned to placebo
decreased (p=0.02)
B: Variation in trial information on
(1) the percentage of patients who
would be assigned to placebo
(10%, 30%, 50%) and (2) the
payment level (payment in range
typically offered to participants in
phase 3 trials of antihypertensive
drugs)
Unclear
Harris et al (UK)31 Factorial Community A: Personal recruitment letter and
info plus telephone reminder (up to
four) plus questionnaire on physical
activity
Not applicable Households of
older people aged
≥65, able to walk
outside and
registered with one
GP practice
69/140 (49.3%) Not applicable A Between-group difference
was statistically significant
for telephone reminders (OR
1.5; 95% CI 1.0 to 2.3), but
not for the inclusion of a
questionnaire (OR 0.9; 95%
CI 0.6 to 1.3)
B: Personal recruitment letter and
info plus telephone reminder (up to
four)
65/140 (46.4%)
C: Personal recruitment letter and
info plus questionnaire on physical
activity
47/140 (33.6%)
D: Personal recruitment letter and
info only
59/140 (42.1%)
Hemminki et al
(Estonia)32
Parallel group Local clinics
(multicentre)
Non-blinded allocation comparing
active HRT treatment with no
treatment
Traditional blinded
allocation comparing
active HRT treatment
with placebo
Postmenopausal
women aged 50–
64
1027/2159
(47.6%)
796/2136
(37.3%)
A Between-group difference
was statistically significant
(p<0.001)
Hutchison et al
(UK)33
Parallel group Secondary
care
Video giving generic and
site-specific trial info with a focus on
randomisation, pictures of patients
receiving care and a voiceover
discussing uncertainty plus
standard practice
Standard practice
of clinician from
tumour site team
discussing trial and
administering trial
specific info sheet
and consent form;
at next visit patient
sees a clinician from
the same team to
decide on treatment
and whether it will be
part of a trial
Patients with
colorectal, breast
or lung cancer,
and eligible for a
cancer treatment
trial
62/86 (72.1%) 66/87 (75.9%) A Considered recruitment to a
range of cancer trials;
between-group difference
was not statistically
significant (p=0.661)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
Ives et al (UK)34 Parallel group Secondary
care
Standard trial information plus
booklet entitled, “Clinical Trials in
HIV and AIDS: Information for
people who are thinking about
joining a trial”
Standard trial
information
(information sheet
specific to proposed
trial plus discussion
with trial doctor and
research nurse)
Patients attending
an HIV hospital
clinic
15/23 (65.2%) 11/27 (40.7%) C Considered recruitment of
patients eligible for
participation in eight trials
being carried out at the
participating institution; no
information on statistical
significance given
Jeste et al
(USA)35
Parallel group Secondary
care
Multimedia consent with DVD
presenting key information from
consent form, including
simultaneous narrative explanation;
researcher also present to answer
questions
Routine consent
procedure plus
10 min control DVD
giving general
information about
research; researcher
also present to
answer questions
Outpatients aged
>40 with
schizophrenia, and
healthy
comparison
subjects
41/62 (66.1%)
patients with
schizophrenia;
23/31 (74.2%)
healthy
comparisons
44/66 (67.2%)
patients with
schizophrenia;
22/29 (75.9%)
healthy
comparisons
B Studied agreement to
participate in a hypothetical
trial; between-group
differences were not
statistically significant (no p
value provided)
Karunaratne et al
(Australia)36
Parallel group Secondary
care
Computer-based, interactive
presentation of study information
inc. diagrams, video clips,
hyperlinks, quiz pages
Conventional
paper-based study
information
Patients aged 18–
70 attending an
outpatient diabetic
clinic
23/30 (76.7%) 17/30 (56.7%) C Considered participant
understanding of consent
materials, including interest
in participating in a
hypothetical trial;
between-group difference
was statistically significant
(p=0.01)
Kendrick et al
(UK)37
Parallel group Primary care
(multicentre)
Mailed invitation to participate in an
injury prevention trial, including a
home safety questionnaire
Mailed invitation to
participate excluding
home safety
questionnaire
Families with
children
aged<5 years,
living in deprived
areas
217/1203 (18.0%) 157/1190
(13.2%)
A Between-group difference
was statistically significant
(p=0.001)
Kerr et al (UK)38 Parallel group Further
education
colleges
(multicentre,
n=5)
A: Leaflet describing a trial of two
treatments for arthritis, where A and
B are described as standard
treatments
Not applicable Students aged
≥18 enrolled on
further education/
leisure courses
24/29 (82.8%) Not applicable C Studied willingness to
participate in a hypothetical
trial; did not provide
recruitment rates (130
participants); between-group
difference was statistically
significant (p<0.001), with
those who had a preference
for a standard treatment—
available outside of the trial
—less willing to participate
than those with no
preference
B: Leaflet describing a trial of two
treatments for arthritis, where A is
described as new treatment and B
as standard treatment
10/17 (58.8%)
C: Leaflet describing a trial of two
treatments for arthritis, where B is
described as new treatment and A
as standard treatment
13/16 (81.3%)
D: Leaflet describing a trial of two
treatments for back pain, where A
and B are described as standard
treatments
26/31 (83.9%)
E: Leaflet describing a trial of two
treatments for back pain, where A is
described as new treatment and B
as standard treatment
10/15 (66.7%)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
F: Leaflet describing a trial of two
treatments for back pain, where B is
described as new treatment and A
as standard treatment
10/16 (62.5%)
Kimmick et al
(USA)39
Cluster Secondary
care and
academic
institutions
(multicentre,
n=126)
Educational intervention of standard
info plus an educational
symposium, geriatric oncology
educational materials, monthly
mailings and emails for 1 year, lists
of available protocols for use on
patient charts, case discussion
seminar
Standard information
of periodic
notification of all
existing CALGB
(Cancer and
Leukaemia Group B)
trials by the CALGB
Central Office, and
CALGB web site
access
Practitioners and
researchers from
CALGB institutions
36% in year 1;
31% in year 2
32% in year 1;
31% in year 2
C Considered recruitment of
older people to existing
CALGB treatment trials for a
range of cancers;
between-group difference
was not statistically
significant at year 1 (p=0.35)
or at year 2 (p=0.83)
Larkey et al
(USA)40
Parallel group Existing trial
sites
(multicentre,
n=2)
A: Hispanic lay advocates; attended
6 h long training sessions, five
quarterly meetings and received
brochures with interest cards to
distribute to other women
Anglo women
controls, received
quarterly ‘phone
calls and brochures
with interest cards to
distribute to other
women
Participants in the
Women’s Health
Initiative trial
13/31 referrals
(41.9%)
2/19 referrals
(10.5%)
B Determined whether
Hispanic women already
enrolled in a study and
trained as lay advocates
would refer/enrol more
participants than untrained
Hispanic women and Anglo
controls; between-group
difference was statistically
significant (p<0.01)
B: Hispanic women controls,
received quarterly ‘phone calls and
brochures with interest cards to
distribute to other women
0/3 referrals
(0.0%)
Liénard et al
(France)41
Cluster Secondary
care
(multicentre,
n=135)
Site visits including an initiation visit
to review trial protocol, inclusion/
exclusion criteria, safety,
randomisation, etc plus ongoing
review visits
No site visits (unless
requested)
Centres recruiting
to an RCT for
breast cancer
302 271 A No denominator data
provided; between-group
difference was not
statistically significant (no p
value provided)
Litchfield et al
(UK)42
Cluster Primary care
(multicentre,
n=28)
Internet-based collection of trial
data
Paper-based
collection of trial data
28 participating
GP practices
45/52 (86.5%) 28/28 (100%) B Considered efficiency and
ease of use of internet
versus conventional
paper-based data capture,
and looked at recruitment
incidentally; between-group
difference was statistically
significant (p=0.04)
Llewellyn-Thomas
et al (Canada)43
Parallel group Secondary
care
A: Booklet with negatively framed
intervention about treatment
side-effects and survival
Booklet with
neutrally framed
intervention about
treatment
side-effects and
survival
Colorectal cancer
patients attending
cancer hospital
outpatients
20/30 (66.7%) 23/30 (76.7%) B Determined the impact of
probabilistic info on entry to
a hypothetical trial;
between-group difference
was not statistically
significant (p>0.40)
B: Booklet with positively framed
intervention about treatment
side-effects and survival
18/30 (60.0%)
Llewellyn-Thomas
et al (Canada)44
Parallel group Secondary
care
Searchable computerised info on
imaginary trial, including purpose,
description of treatment arm and
randomisation, possible benefits,
side-effects, patients’ rights
Tape-recorded info
on imaginary trial,
including purpose,
description of
treatment arm and
Patients attending
the outpatient
department of a
cancer hospital
31/50 (62.0%) 21/50 (42.0%) B Studied recruitment to a
hypothetical trial;
between-group difference
was statistically significant
(p<0.05, unadjusted)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
randomisation,
possible benefits,
side-effects, patients’
rights
Mandelblatt et al
(USA)45
Parallel group Community
(multicentre,
n=3)
5–10 min educational counselling
session about the trial delivered by
non-physician study staff (inc
benefits and risk of participation and
need for minority participation) plus
an informational brochure
Informational
brochure only
Spanish speaking
women who were
eligible for a trial
on women at high
risk of breast
cancer
178/232 (76.7%)
general
intent;118/232
(50.9%) if mild
side-effects
mentioned;108/
232 (46.6%) if
uterine cancer
mentioned
147/218 (67.4%)
general
intent;118/218
(54.1%) if mild
side-effects
mentioned;97/
218 (44.5%) if
uterine cancer
mentioned
C Results relate to intention to
participate (‘might, probably
or definitely would’);
between-group difference
was statistically significant
for general intention to
participate (p=0.03)
Miller et al (USA)46 Parallel group Secondary
care, primary
care and
community
Eligibility screening and recruitment
by a senior investigator
Eligibility screening
and recruitment by a
Research Assistant
Patients aged
18–75, eligible for
participation in two
chronic depression
treatment trials
28/162 (17.3%) 22/185 (11.9%) C Considered the relationship
between interviewer
experience and positive
predictive value and cost of
telephone screening, and
looked at recruitment
incidentally; between-group
difference was not
statistically significant
(p=0.30)
Monaghan et al
(Worldwide)47
Cluster Existing trial
sites
(multi-centre,
n=167)
Additional communication—usual
plus frequent emails, regular
personalised mail-outs of league
tables/graphs of performance
against other sites, certificates of
achievement for recruitment/other
study items (1/month)
Usual
communication
(provided via the
regional centre) plus
occasional direct
communications
from the
co-ordinating centre
in the form of
generic newsletters,
emails and faxes
Clinical sites in 19
countries
recruiting to a
diabetes and
vascular disease
treatment trial
37.5 (27.0–51.5) 37.0 (21.0–54.5) A Result provided as median
number of participants
recruited; between-group
difference was not
statistically significant
(p=0.68)
Myles et al
(Australia)48
Parallel group Secondary
care
A: Prerandomised to experimental
drug and asked to provide consent;
if no consent, standard treatment
given
Standard
randomisation
method (equal
chance of either
drug)
Inpatients aged
≥18, scheduled for
elective surgery
90/169 (53.3%) 84/151 (55.6%) B Considered recruitment to a
hypothetical trial;
between-group difference
was not statistically
significant (p=0.66)B: Prerandomised to standard drug
and asked to provide consent; if no
consent, experimental treatment
given
79/149 (53.0%)
C: Told that physician thinks
experimental drug superior, if
consent given, has 70% chance of
receiving this; if no consent,
standard treatment given
91/150 (60.7%)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
D: Allowed to increase or decrease
chance of receiving experimental
drug if consent given, and if no
preference, 50% chance of
receiving it; if no consent, standard
treatment given
85/150 (56.7%)
Nystuen and
Hagen (Norway)49
Parallel group Community
(multicentre,
n=6)
Written invitation to participate in a
community-based trial followed by a
‘phone reminder if no response
within 2 weeks; guide used for
discussion
Written invitation to
participate in a
community-based
trial followed by no
reminder if no
response within
2 weeks
Sick-listed
employees
attending a
participating social
security office
31/256 (12.1%) 11/242 (4.5%) A Between-group difference
was statistically significant
(p=0.003)
Perrone et al
(Italy)50
Parallel group Community A: randomised consent to new
treatment; if no consent given
standard treatment
On consent to
participate, standard
or new treatment
assigned at random;
if no consent, given
standard treatment
Members of the
general public
aged 16–80,
attending a
scientific exhibition
997/1151 (86.6%) 836/985 (84.9%) C Studied recruitment to a
hypothetical trial;
between-group difference
was significant for both the
single (p=0.08) and double
consent scenarios
(p<0.0001)
B: randomised consent to standard
treatment; if no consent given new
treatment
246/474 (51.9%)
C: if consents to participate,
standard or new treatment assigned
at random; if no consent, can
choose standard or new treatment
482/607 (79.4%)
Pighills et al
(UK)51
Parallel group Primary care
(multicentre)
A: Newspaper article about the trial
included with recruitment materials
Usual recruitment
materials only
Men and women
aged ≥70 who
had at least one
fall in the previous
12 months
73/2243 (3.3%) 71/2245 (3.2%) B Evaluated interventions in
separate trials;
between-group differences
were not statistically
significant (p=0.80; p=0.62)
B: Inclusion of a more ‘upbeat’
newspaper article about the trial
Inclusion of the
Intervention A
newspaper article
57/1374 (4.1%) 54/1371 (3.9%)
Simel and
Feussner (USA)52
Parallel group Secondary
care
Consent form including a statement
that the new treatment may work
twice as fast as usual treatment
Consent form
including a statement
that the new
treatment may work
half as fast as usual
treatment
Patients attending
an ambulatory
care clinic
35/52 (67.3) 20/48 (41.7%) B Considered recruitment to a
hypothetical trial;
between-group difference
was statistically significant
(p<0.01)
Simes et al
(Australia)53
Parallel group Secondary
care
Individual approach to consent—
patients given info about aims,
expected results, potential toxicities
of treatment; details of treatment left
to discretion of consultant; patients
given opportunity to ask questions,
verbal consent obtained
Total disclosure
approach—patients
fully informed about
all trial aspects by
consultant: patients
given opportunity to
ask questions, also
given a consent form
outlining the info; this
was kept overnight
and written consent
obtained next day
Patients attending
an oncology unit
27/29 (93.1%) 23/28 (82.1%) A Considered recruitment of
patients eligible for 16 trials
being carried out at the
participating institution;
between-group difference
was statistically significant
(p=0.01)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
Treschan et al
(Austria)54
Parallel group Secondary
care
A: Info on study of wound healing
said to have no risk but involving
additional procedures described as
provoking considerable pain and
discomfort
Info on study of
wound healing
described as posing
essentially no risk
and producing no
significant pain
Patients aged 19–
80, and scheduled
for minor surgery
with general
anaesthesia
18/51 (35%) 30/47 (64%) B Studied willingness to
participate in a hypothetical
trial, although patients were
not aware of this until after
the decision to take part;
between-group difference
was statistically significant
(p<0.001)
B: Info on study of wound healing
said to have no pain but involving
additional procedures described as
inducing risk of injury
13/50 (26%)
Trevena et al
(Australia)55
Sequential
start
Primary care Opt-out recruitment; letter from
doctor advising that practice taking
part in screening trial; would be
contacted unless practice advised
to withhold contact details
Opt-in recruitment;
letter from doctor
advising that practice
taking part in
screening trial; would
only be contacted if
contact details
returned
Patients aged 50–
74 eligible for a
colorectal cancer
screening trial
40/60 (66.7%) 44/92 (47.8%) A Compared the effect of
opt-in requirements in new
privacy laws with an opt-out
approach that was
previously permissible; no
information on statistical
significance given
Wadland et al
(USA)56
Parallel group Primary care Consent form read out to potential
participants by study co-ordinator
Consent form read
by potential
participants
Current smokers
aged ≥18
27/51 (53%) 25/53 (47%) C Smoking cessation study
carried out in two practices,
with the intervention
evaluated in one;
between-group differences
were not statistically
significant (no p value
provided)
Weinfurt et al
(USA)57
Parallel group Secondary
care
A: Consent documents containing a
disclosure indicating that the clinic
received per capita payments
covering the costs of the research
(including investigator’s salary)
Consent documents
containing no
financial disclosure
Patients of a
cardiovascular
outpatient clinic
aged ≥18, and
diagnosed with
coronary artery
disease
3.51 (SD 1.30) 3.50 (SD 1.29) C Studied willingness to
participate in a hypothetical
trial; did not provide
recruitment rates (470
participants); results
provided as mean
willingness scores;
between-group difference
was statistically significant
(p=0.02); patients in the
equity group were also less
willing to participate than
those in the per capita
(p=0.01) and no disclosure
groups (p=0.03)
B: Consent documents containing a
disclosure describing an investment
by the investigator in the company
sponsoring the research (‘equity’)
3.20 (SD 1.32)
Weinfurt et al
(USA)58
Parallel group Community A: Info inc a general disclosure that
the investigator may gain financially
from the study plus a statement that
ethics committee does not think this
affects patient safety or study
quality
Not applicable Aged ≥18 with
asthma or
diabetes and a
member of a panel
of adults who
agreed to be
contacted about
research
opportunities
3.28 (SD 0.04) Not applicable C Studied willingness to
participate in a hypothetical
trial; did not provide
recruitment rates (3623
participants); results
provided as mean
willingness scores;
between-group difference
B: Info inc a disclosure that the drug
company pays running costs to the
investigator plus a statement that
3.46 (SD 0.04)
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Table 1 Continued
Authors
(country) RCT design Setting Intervention(s) Comparator Participants
Recruited to
intervention(s)
Recruited to
comparator
Risk
of
bias* Comments†
was statistically significant
(p<0.001)
ethics committee does not think this
affects safety or quality
C: Info inc a disclosure that the drug
company pays monies out with the
study to the investigator plus a
statement that ethics committee
does not think this affects safety or
quality
3.22 (SD 0.04)
D: Info inc a disclosure that the
investigator has an investment in
the drug company plus a statement
that ethics committee does not think
this affects safety or quality
3.16 (SD 0.04)
E: Info inc a disclosure that the
investigator’s institution has an
investment in the drug company
plus a statement that ethics
committee does not think this
affects safety or quality
3.28 (SD 0.04)
Welton et al
(UK)59
Parallel group Primary care
(multicentre,
n=10)
Verbal info about a trial of HRT,
comparing oestrogen only, with
combined oestrogen and
progestogen, with placebo
Verbal info about a
trial of HRT,
comparing oestrogen
only with combined
oestrogen and
progestogen
Women aged 45–
64 who had not
had a
hysterectomy
65/218 (29.8%) 85/218 (39.0%) C Considered willingness to
take part in a hypothetical
trial; between-group
difference was not
statistically significant
(p=0.06)
Weston et al
(Canada)60
Parallel group Secondary
care
(multicentre)
Written study information followed
by viewing of Term Prelabour
Rupture of the Membranes (Term
PROM) video
Written study
information only
Women attending
for antenatal visits
26/42 (61.9%)
initially; 23/41
(56.1%) at 2–
4 weeks
17/48 (35.4%)
initially; 17/44
(38.6%) at 2–
4 weeks
B Between-group difference
was statistically significant
(p=0.01)
*Risk of bias: A, low; B, moderate; C, high.
†Includes difference in outcomes as reported by the authors.
RCT, randomised controlled trial.
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not possible to determine actual participant numbers
for two studies aimed at recruiters. In a further six
studies evaluating recruitment to hypothetical trials,
the number willing to participate was unclear, or was
reported as a mean score. In more than half of the
studies, participants were recruited from secondary care
(n=23), or from secondary care in combination with
another setting (n=2). Trials based in the community
(n=8) or in primary care (n=6) were also common
(table 1).
Risk of bias within studies
All of the studies were described by their authors as
being either randomised (n=41) or quasi-randomised
(n=4), but more than a third failed to provide details of
the method used to achieve this. Similarly, while alloca-
tion concealment was adequate in half of the studies,
details were poorly reported in many others. This was
also true in relation to the procedures used to blind par-
ticipants, which was often missing or not fully reported.
All studies provided details on the outcome measures
used, many of which were subjective (eg, willingness or
intention to consent). When considered across the
domains, 12 studies had a low risk of bias, 13 had mod-
erate risk and 20 had a high risk (table 1).
Effects of interventions on recruitment
The 45 included studies evaluated 46 interventions
across six main categories: trial design, obtaining
consent, approach to participants, ﬁnancial incentives,
training for recruiters and trial co-ordination (table 2).
As might be expected, the majority of studies were
aimed directly at trial participants (n=40), with few
studies targeting those responsible for recruitment.
Although some of the categories incorporate several
studies, we considered the majority of interventions to
be sufﬁciently different to make pooling them inappro-
priate. Where reported data did not allow for calculation
of an estimate of effect based on our outcome measure,
the results from the paper have been presented. Effects
of the interventions studied are presented in table 3 and
ﬁgures 2–7; only those ﬁgures relating to pooled esti-
mates have been presented.
Trial design
Six studies (5675 participants; one study also recruited
28 general practices) considered the effect of trial
design changes on recruitment.
Two trials16 32 compared an open design (where parti-
cipants know what treatment they are receiving) with a
blinded, placebo-controlled design, and found that an
open design improved trial recruitment (RR 1.22, 95%
CI 1.09 to 1.36; ﬁgure 2). A study investigating the
impact of a placebo group on women’s willingness to
participate in a hypothetical hormone replacement
trial59 suggests that the number likely to take part may
be less when a non-active comparator is included
(RR 0.76, 95% CI 0.59 to 0.99). A trial of menorrhagia
management compared conventional randomisation
with a patient preference design, where those with a
preference for a speciﬁc treatment receive it, while the
remainder are randomised.18 Although this made little
or no difference to the number who agreed to be
recruited to the trial, women were more likely to partici-
pate in the study overall (96% vs 70%).
In a crossover trial for palliative care, cluster random-
isation was compared with consenting individuals after
randomisation if they were assigned to experimental
treatment (Zelen design).25 Only two sites with few parti-
cipants were included (6/24 recruited in the cluster arm
vs 0/29 in the Zelen arm; p=0.02). The ﬁnal study
involved 28 general practices in a trial of two delivery
methods for insulin, and compared internet-based data
capture with paper-based collection, reporting higher
recruitment with the paper-based method (45/52 vs
28/28; p=0.04).42
Obtaining consent
Five studies (4468 participants) considered modiﬁca-
tions either to the consent process (including timing) or
to the format of the consent form.
Consent process
In a trial on decision aids for colorectal cancer screen-
ing,55 the use of opt-out (potential participants were
contacted unless they withdrew their details) was found
to improve recruitment when compared with an opt-in
approach to contact (RR 1.39, 95% CI 1.06 to 1.84).
Two studies recruiting to hypothetical trials (one on a
new drug and one on anaesthesia) evaluated various
combinations of prerandomisation and consent.48 50
Both evaluated consenting speciﬁcally for the experi-
mental or standard treatment, but there was consider-
able heterogeneity for the latter (I2=93%), and under a
random-effects model, neither form of consent may lead
to any difference in recruitment (ﬁgure 3). Three other
variants of consent were also considered: (1) consent
allowing those refusing participation to choose between
the treatments,50 (2) consent to a 70% chance of receiv-
ing the experimental treatment because the clinician
believes it is better48 and (3) consent to a participant-
modiﬁed chance of receiving the experimental treat-
ment (60%, 70% and 80%).48 All three appear to have
had little effect on recruitment compared with usual
consent.
Consent format
Two trials dealt with how the consent form was pre-
sented to potential participants. Researchers in a
smoking cessation trial56 compared the effect of the
consent form being read aloud by the researcher with it
being read by participants, while a cluster trial recruiting
to oncology studies evaluated an easy-to-read version of
the consent form.19 Neither study found that the inter-
vention improved recruitment.
14 Treweek S, Lockhart P, Pitkethly M, et al. BMJ Open 2013;3:e002360. doi:10.1136/bmjopen-2012-002360
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Approach to participants
Twenty-eight studies (31 910 participants) evaluated the
effect of modifying trial information or the way it was
delivered.
Delivery of trial information
Nine studies considered various ways of providing poten-
tial participants with information about the trial. Studies
using video or other audiovisual materials had mixed
results. A study evaluating the effect of providing a
10 min video alongside written information in a trial
of pregnant women with prelabour rupture of
membranes60 found that this most likely improved will-
ingness to participate compared with written informa-
tion alone (RR 1.75, 95% CI 1.11 to 2.74). There were
three studies presenting audiovisual overviews of clinical
Table 2 Recruitment intervention and effect on participation
Recruitment interventionReference ID Increases Decreases Little impact Inconclusive
Trial design
Open design16 32 †
Placebo* 59 W_
Patient preference design18 W_
Zelen design†25 W_
Internet-based data capture†42 W_
Obtaining consent
Process—opt-out approach55 W_
Process—consent to experimental treatment*48 50 †
Process—consent to standard treatment*48 50 †
Process—refuser chooses treatment option*50 W_
Process—physician modified chance of experimental*48 W_
Process—participant modified chance of experimental*48 W_
Form—researcher read aloud56 W_
Form—altered readability level†19 W_
Approach to participants
Delivery—video presentation*†28 35 †
Delivery—video presentation plus written information60 W_
Delivery—audiovisual overview of trials21 22 33 †
Delivery—interactive computer presentation*36 44 †
Delivery—verbal education session45 W_
Supplementing info—booklet on clinical trials*23 34 †
Supplementing info—study-relevant questionnaire31 37 †
Supplementing info—newspaper article51 W_
Framing—treatment as faster*52 W_
Framing—treatment as new*38 W_
Framing—emphasis on pain or risk*54 W_
Framing—positively or negatively*43 W_
Content—more detailed info (inc. total disclosure)*27 53 †
Content—financial disclosure of investigator interest*†57 58 †
Telephone reminders31 49 †
SMS messages26 W_
Eligibility screening—face-to-face*24 29 †
Eligibility screening—telephone*20 W_
Eligibility screening—electronic self-complete*29 W_
Screening personnel46 W_
Financial incentives
Cash incentive with invitation26 W_
Paid participation*†17 30 †
Level of trial risk*†17 30 †
Training for recruiters
Training lay advocates†40 W_
Education sessions†39 W_
Trial co-ordination
On-site visits†41 W_
Additional communication†47 W_†, Multiple studies; W_ , single study.
*Includes recruitment to hypothetical trial(s).
†Includes result reported by study authors only (effect size not calculated).
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Table 3 Effects of interventions to improve recruitment
Intervention Reference ID
Participants recruited Risk ratio
(95% CI)
Absolute
difference (%)*
Heterogeneity Risk of bias†
(studies)Intervention Comparator χ2 p Value I2 (%)
Trial design
Open vs blind design16 32 1161/2339 1029/2494 1.22 (1.09 to 1.36) 9 2.74 0.10 64 A│A (2)
Active comparator vs placebo59‡ 65/218 85/218 0.76 (0.59 to 0.99) −9 – – – C (1)
Patient preference vs conventional
RCT18
90/135 97/138 0.95 (0.81 to 1.11) −4 – – – A (1)
Obtaining consent
Consent process Opt-out vs opt-in55 40/60 44/92 1.39 (1.06 to 1.84) 19 – – – A (1)
Consent to experimental vs
usual48‡, 50‡
1087/1320 920/1136 1.01 (0.98 to 1.05) 1 0.42 0.51 0 B│C (2)
Consent to standard vs usual48‡, 50‡ 325/623 920/1136 0.76 (0.49 to 1.17) −19 14.74 <0.001 93 B│C (2)
Refusers choose treatment vs
usual50‡
482/607 836/985 0.94 (0.89 to 0.98) −5 – – – C (1)
Physician modified consent vs
usual48‡
91/150 84/151 1.09 (0.90 to 1.32) 5 – – – B (1)
Participant modified consent vs
usual48‡
85/150 84/151 1.02 (0.83 to 1.24) 1 – – – B (1)
Consent form Researcher read vs
participant read56
27/51 25/53 1.12 (0.76 to 1.65) 6 – – – C (1)
Approach to participants
Delivery of information Full video
presentation+Q&A vs standard info
+brief video+Q&A35‡
64/93 66/95 0.99 (0.82 to 1.20) −1 – – – B (1)
Video presentation+written
information vs written only60
26/42 17/48 1.75 (1.11 to 2.74) 26 – – – B (1)
Audiovisual information on trials vs
standard21 22 33
88/247 82/248 1.20 (0.75 to 1.91) 7 4.00 0.14 50 B│C│A (3)
Interactive computer presentation vs
paper-based information36‡
23/30 17/30 1.35 (0.93 to 1.96) 20 – – – C (1)
Interactive computer presentation vs
audio-taped information44‡
31/50 21/50 1.48 (1.00 to 2.18) 20 – – – B (1)
Verbal educational session
+information brochure vs brochure
only45
178/232 147/218 1.14 (1.01 to 1.28) 9 – – – C (1)
Supplementing information Booklet on
trials+standard information vs standard
information only23‡, 34
27/53 25/57 1.18 (0.64 to 2.18) 8 2.38 0.12 58 C│C (2)
Study questionnaire with invitation vs
invitation only31 37
333/1483 281/1470 1.14 (0.77 to 1.64)§ 3 4.41 0.04 77 A│A (2)
Continued
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Table 3 Continued
Intervention Reference ID
Participants recruited Risk ratio
(95% CI)
Absolute
difference (%)*
Heterogeneity Risk of bias†
(studies)Intervention Comparator χ2 p Value I2 (%)
Newspaper article+study information
vs study information only51
73/2243 71/2245 1.03 (0.75 to 1.42) 0 – – – B (1)
Favourable article+information vs
standard article+information51
57/1374 54/1371 1.05 (0.73 to 1.52) 0 – – – B (1)
Framing and content Treatment
described as working ‘twice as fast’ vs
‘half as fast’52‡
35/52 20/48 1.62 (1.10 to 2.37) 26 – – – B (1)
Trial of treatment described as new
vs treatment described as
standard38‡
43/64 50/60 0.81 (0.66 to 0.99) −16 – – – C (1)
Information emphasising pain
involved vs standard information54‡
18/51 30/47 0.55 (0.36 to 0.85) −29 – – – B (1)
Information emphasising risk
involved vs standard information54‡
13/50 30/47 0.41 (0.24 to 0.68) −38 – – – B (1)
Negative framing vs neutral framing
of side-effects/survival43‡
20/30 23/30 0.87 (0.63 to 1.20) −10 – – – B (1)
Positive framing vs neutral framing of
side-effects/survival43‡
18/30 23/30 0.78 (0.55 to 1.11) −17 – – – B (1)
Total information disclosure vs
standard disclosure53
27/29 23/28 1.13 (0.93 to 1.38) 11 – – – A (1)
Less detailed information on risk and
benefits vs more detailed
information27‡
4/10 3/9 1.20 (0.36 to 3.97) 7 – – – B (1)
Information leaflet+verbal
explanation vs information leaflet
only27‡
10/18 7/19 1.51 (0.73 to 3.10) 19 – – – B (1)
Telephone contact Telephone reminder
vs no reminder31 49
165/536 117/522 1.66 (1.03 to 2.46)§ 15 2.44 0.12 59 A│A (2)
SMS messages (inc quotes) vs no
SMS messages26
17/405 0/406 35.09 (2.12 to 581.48) 4 – – – A (1)
Eligibility screening Enhanced
recruitment (inc African American
interviewer) vs standard24
78/3079 95/3297 0.88 (0.65 to 1.18) 0 – – – B (1)
Enhanced recruitment+baseline data
by telephone vs standard24
87/3075 95/3297 0.98 (0.74 to 1.31) 0 – – – B (1)
Enhanced recruitment+baseline data
face-to-face vs standard24
116/2949 95/3297 1.37 (1.05 to 1.78) 1 – – – B (1)
Researcher-administered screening
questionnaire vs standard paper
based29‡
42/78 76/141 1.00 (0.77 to 1.29) 0 – – – C (1)
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trials (including risks and beneﬁts, randomisation and
value to society) for a range of cancer studies (ﬁgure
4),21 22 33 one using interactive computer information in
a hypothetical trial on managing complications after
heart attack36 and another using video plus a pamphlet
for a hypothetical HIV vaccine trial,28 but all found little
or no difference in recruitment.
Interactive computer presentation compared with audio-
taped presentation in a hypothetical cancer trial44 slightly
improved recruitment (RR 1.48, CI 95% 1.00 to 2.18),
while showing a multimedia presentation of key trial infor-
mation while a research assistant was available to answer
questions, appears to have had little impact compared with
just the research assistant in a hypothetical drug trial for
schizophrenia.35 Finally, a study using a brief verbal educa-
tion session for Spanish-speaking women eligible for a trial
on high breast cancer risk45 found slightly improved
recruitment compared with print materials alone (RR 1.14,
95% CI 1.01 to 1.28).
Supplementing trial information
Five studies considered the effect of supplementing
usual trial information with additional materials. Two
studies evaluated the inclusion of a booklet on clinical
trials, one in a hypothetical breast cancer trial,23 the
other in a real trial for HIV patients,34 while two trials
on physical activity31 and injury prevention37 included
study-relevant questionnaires with the invitation letters
to potential participants. All four interventions made
little or no difference to recruitment (ﬁgures 5 and 6).
In the ﬁnal study, the authors investigated the effect of
including a newspaper article publicising the trial.51
This led to little or no difference in recruitment, even
when the article was replaced with one that was more
favourable to the trial.
Framing and content of trial information
Eight studies evaluated modiﬁcations to the way study
information was presented, seven of them for hypothet-
ical trials. The only study to evaluate an intervention for
a real trial compared total disclosure of information
relevant to a cancer trial with a more limited individual
approach, where the level of detail was at the clinician’s
discretion.53 This found that providing more informa-
tion led to little or no difference in recruitment.
Similarly, a study comparing a more detailed informa-
tion leaﬂet with a less detailed one in a hypothetical
cancer trial also found that this made little or no
difference.27
A consent form describing a new medication that
‘may work twice as fast as usual treatment’ most likely
increased recruitment compared with one describing it
as working ‘half as fast’ (RR 1.62, 95% CI 1.10 to
2.37),52 while describing treatment as ‘new’ rather than
‘standard’ may have slightly decreased recruitment
(RR 0.81, 95% CI 0.66 to 0.99).38 Similarly, emphasising
the pain or risk involved in a trial most likely decreased
recruitment (RR 0.55, 95% CI 0.36 to 0.85 and RR 0.41,
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95% CI 0.24 to 0.68, respectively).54 Neutrally framed
information about side effects and survival compared
with negatively or positively framed information43
appears to have led to little or no difference in
recruitment.
Two studies investigated the effects of disclosing the
ﬁnancial interests of those involved in the trial. In the
ﬁrst, a hypothetical heart disease trial, three scenarios
outlining the investigators’ interests were presented.57
Willingness to participate reduced when the investigator
had an investment in the drug company, compared with
no disclosure (p=0.03) or per capita research payments
to the investigating institution (p=0.01). In the second
study, ﬁve scenarios were presented to research-
interested adults with asthma or diabetes.58 Again, will-
ingness to participate was lowest when the investigator
had an investment in the drug company, and highest
when the company paid the running costs (p<0.001).
Telephone contact
Three studies used telephones as a means of contacting
potential participants. Two trials (on returning sick-listed
people to work49 and activity in older people31) found
that using telephone reminders to follow-up written invi-
tations improved recruitment (OR 1.95 95% CI 1.04 to
3.66; ﬁgure 7), although there was moderate heterogen-
eity related to the magnitude of effect (I2=59%). In the
third study, a series of SMS messages containing quotes
from existing recruits were texted to potential partici-
pants of a smoking cessation trial.26 This improved
recruitment compared with the standard written invita-
tion (RR 35.09, 95% CI 2.12 to 581.48), although small
numbers overall led to a wide CI.
Eligibility screening
Four studies considered the use of different methods
for screening potentially eligible participants. In a
study recruiting African Americans to a cancer trial,24
conducting baseline screening and data collection at
face-to-face church sessions most likely improved recruit-
ment compared with standard procedures (RR 1.37,
95% CI 1.05 to 1.78). In two other studies evaluating
willingness to take part in a hypothetical lifestyle trial,
face-to-face (researcher) eligibility screening was com-
pared with telephone screening,20 and with varied
methods of participant self-completion of a screening
questionnaire.29 Telephone screening may have
improved willingness to participate compared with
researcher administration20 (RR 1.26, 95% CI 1.06 to
1.50), but neither face-to-face administration nor elec-
tronic completion led to any difference in recruitment
compared with standard self-completion on paper.29
A fourth study recruiting to chronic depression treat-
ment trials46 incidentally reported on the inﬂuence of
screening personnel, comparing senior investigators
with research assistants, but this had little impact on
recruitment.
Financial incentives
Three studies involving 1698 participants evaluated the
effects of offering ﬁnancial incentives on recruitment.
In one smoking cessation trial, the inclusion of a monet-
ary incentive (GBP £5) with the study information and
consent form was found to increase recruitment
(RR 12.95, 95% CI 1.71 to 98.21).26 In two other studies,
the incentive was payment for participation (in a hypo-
thetical trial), which was varied relative to the risk
Figure 3 Recruitment with
consent to experimental, standard
and usual consent procedure.
Figure 2 Recruitment with open
and blinded trial design.
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involved. One study combined three levels of trial risk
(high, medium and low) with three levels of payment
($1800, $800 and $350),17 while the other varied the
payment levels ($2000, $1000 and $100) and the risk of
adverse drug effects or of receiving placebo in a hypo-
thetical antihypertensive drug trial.30 Both studies
found that willingness to participate increased with
payment (p=0.015, p<0.001, respectively) in one case,
regardless of the associated risk.17
Training for recruiters
Two studies, one with 98 recruiters and the other with
126 recruiting centres, considered interventions
aimed at those recruiting, both involving educational
packages.39 40 One study evaluated training Hispanic
participants in a prevention trial as lay advocates—
Embajadoras—to refer other Latinas to the study.40 Data
analysis did not correct for clustering and no ICC was
provided, but the authors reported that more
Embajadoras recruited to the trial than either untrained
Hispanic or Anglo controls (8/28 vs 0/26 and 2/42,
respectively). The second study, a cluster trial involving
126 centres in a cancer and leukaemia research
network, compared the standard input for recruiters
with an educational package (including a symposium
and monthly mailings) aimed at improving recruitment
of older participants.39 Although centre-level data and
ICC were not provided, clustering was considered in the
analysis, and the authors found that additional educa-
tion did not signiﬁcantly inﬂuence recruitment (31% vs
31%, p=0.83).
Trial co-ordination
Two studies involving a total of 302 trial sites looked at
the effect of greater contact from the trial co-ordinators.
In the ﬁrst, a breast cancer trial, 68 of the 135 recruiting
centres received on-site visits (including an initiation
visit to review the trial protocol, etc), while the remain-
der received none.41 In the second, an international dia-
betes trial, additional communication from the
co-ordinating centre (frequent emails, individually
tailored feedback on recruitment, etc) was compared
with usual communication.47 Neither study presented
the proportion of eligible participants, but both
reported ﬁnding little difference in recruitment when
site visits were made (302 with visits vs 271 with no
visits), or when communication was increased (median
number of recruits 37.5 vs 37.0 for standard
communication).
DISCUSSION
Principal findings
In this systematic review, we assessed the evidence from
45 trials evaluating the effect of intervention strategies
designed to improve recruitment to randomised con-
trolled trials. We found that a number of interventions
do appear to be effective, although the evidence base
related to some is still limited. Telephone reminders to
non-responders,31 49 opt-out procedures requiring
potential participants to contact the research team if
they do not want to be contacted about a trial,55 includ-
ing a ﬁnancial incentive with the trial invitation,26 and
making the trial open rather than blinded16 32 all
improved recruitment in high-quality studies involving
real trials. The effect of other strategies to improve
recruitment, however, remains less clear.
Although partial preference designs may improve par-
ticipation in a study as a whole, they appear to have little
impact on recruitment to randomisation,18 and with the
exception of the opt-out approach already mentioned, a
variety of strategies involving changes to consent proce-
dures failed to produce any increase in recruitment.
Similarly, modiﬁcations to the method or quantity of infor-
mation presented to potential participants—either about
trials in general or about a speciﬁc trial—did not provide
clear evidence of the beneﬁt of this approach to improving
recruitment. Providing information to prospective partici-
pants in the form of quotes from existing participants via
SMS shows potential, but it was evaluated in a single
study,26 and requires further evaluation. Few studies
looked at interventions aimed not at potential participants
Figure 4 Recruitment with
audiovisual and standard trial
information.
Figure 5 Recruitment with
clinical trials booklet and standard
trial information.
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but at those recruiting them,39–41 47 and none presented
clear evidence in favour of the strategies used.
While several of the interventions studied show
promise, there are some caveats. Pooled analysis for
telephone reminders had moderate heterogeneity
(I2=59%), although it would appear that it is the magni-
tude of effect rather than the beneﬁt of the intervention
that is in doubt. Similarly, while the inclusion of a ﬁnan-
cial incentive as used by Free et al26 did improve recruit-
ment, the number of participants recruited was small,
leading to uncertainty about the magnitude of effect.
Two additional studies involving ﬁnancial incentives
found that increasing payment led to increased recruit-
ment,17 30 but these involved hypothetical trials as well
as sums of money that might not be feasible when
recruiting to real studies. In addition, ethical concerns
have been raised about the use of some of these strat-
egies. Telephone reminders and ﬁnancial incentives
have both been used and accepted by many as a legitim-
ate recruitment tool, but they may be considered by
some to be a form of coercion. Opt-out procedures have
previously been proposed as a way of improving recruit-
ment to health research,61 but this approach remains
controversial, as ethics committees generally require that
research participants provide express approval for
research participation, including being contacted about
the study by researchers. However, it is worth noting that
the trial included in this review55 studied opting-out of
being contacted about a trial rather than opting-out of
consenting to trial participation. This may be viewed as
being less controversial, and as such, ethics committees
may be more willing to accept it as part of a recruitment
strategy. Finally, while it may be easier to recruit to an
open trial rather than a blinded trial, there is clearly a
greater risk of bias involved, and it is therefore an
approach that requires careful consideration before
being implemented.
Limitations of the review
Many of the studies included in this review were small,
likely to be underpowered and with CIs including the
possibility of substantial beneﬁt. This is particularly true
of interventions that modiﬁed the approach made to
potential participants. In addition, 19 studies involved
hypothetical trials, and the implications of their results
for real trials are still unclear.
The interventions used by studies varied signiﬁcantly,
making it difﬁcult to pool data. Even those studies
adopting the same basic approach, such as altering the
consent process, were generally sufﬁciently different
to make pooling inappropriate.62 For example, while
there were ﬁve studies of seven interventions looking at
changes to consent procedures, only two interventions
were comparable enough to be pooled. Similarly, video
presentations were used in six studies but generally deliv-
ered different information, or were used in combination
with other interventions that differed between studies.
Consequently, only three could be combined in the
same analysis. At the outset of the review, we had
planned to undertake a number of subgroup analyses of
the key factors considered relevant to heterogeneity, but
variations in the interventions themselves would have
made these comparisons meaningless. One such sub-
group related to the impact of recruiting to a hypothet-
ical trial versus a real trial. There was, however, only one
comparison where there was at least one of each type of
trial, and we were therefore unable to assess this factor.
Only one of the cluster trials31 provided sufﬁcient data
to allow an appropriate analysis to be incorporated in
the review. In addition, there were a number of studies
which potentially had data clustered by the study the
participant was invited to join, even though participants
were individually randomised. As such, estimates from
these studies may be overly precise.
Potential bias was also a problem in many of the
studies, often linked to hypothetical trials. Although allo-
cation concealment was considered high quality for 22
of the 45 trials (it was unclear for 16 and poor for 7),
the overall assessment of the risk of bias was considered
as low for only 12 studies. Twenty trials were considered
to be at a high risk of bias. It was not possible to predict
the direction of effect that any bias may have had on
Figure 6 Recruitment with
invitation including study
questionnaire and standard
invitation.
Figure 7 Recruitment with
telephone reminder and standard
follow-up.
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study outcomes. In addition, we were unable to make
statistical judgements about the likelihood of publication
and related biases due to the relatively small number of
included studies per comparison, and the wide variation
in the recruitment strategies being evaluated.
However, this review provides an update to previous
reviews in the ﬁeld, identifying a greater number of rele-
vant studies and presenting new evidence relating to
trial design (the potentially negative impact of using a
Zelen design), the approach to participants (the beneﬁts
of using SMS messages, framing of trial information,
ﬁnancial disclosure) and ﬁnancial incentives (including
a cash incentive with the trial invitation). In addition, it
has generated further evidence to support the broad
conclusions from earlier work, namely that opt-out
procedures, open rather than blinded trials, paid partici-
pation and telephone reminders to non-responders
improve recruitment, while various methods of consent
and the provision of supplementary information appear
to have little effect.
Implications for research
The ﬁndings from this review would suggest that there
are two key areas within recruitment-related research
where activity could be focused. First, despite the failure
of many trials to meet their recruitment targets, and the
signiﬁcant implications of this both practically and in
relation to the delayed application of effective interven-
tions,2–6 few strategies designed to improve trial partici-
pation have been rigorously evaluated in the context of
a real trial. Almost half of the trials in this review
involved hypothetical studies, including many of those
evaluating changes to the consent process, and all but
one of those looked at the use of ﬁnancial incentives.
In some of these studies, there was evidence of beneﬁt.
In others, the intervention demonstrated little impact.
But what is true for all is that their effect in a real setting
is unknown. Given that, we would argue that while the
use of hypothetical trials to study recruitment interven-
tions has its place, trialists should include evaluations of
their recruitment strategies within their trials, and
research funding bodies should support this as part of
future trial methodologies. Where uncertainty exists
around two or more strategies, an evaluation could actu-
ally help trialists to focus their efforts on the most effect-
ive strategy (or strategies) while at the same time adding
to the methodological literature. If recruitment is
carried out in phases, evaluation could be used in the
early phases with later phases employing the most effect-
ive strategies identiﬁed.63 Since everyone receiving a
recruitment intervention ‘counts’ for the evaluation—
the study is simply counting the number of yes and no
responses—statistical power is generally not a problem.
Graffy et al64 have discussed nested trials of recruitment
interventions in more detail.
Second, previous research on potential barriers to trial
participation has suggested that there are various factors
that may provide the means by which recruitment can
be increased, many of them related to trial recruiters.
These include evaluating a clinically important question,
minimising the workload of participating clinicians,
removing responsibility for consent away from clinicians
and involving research networks.65–67 Only 4 of the 45
studies included in this review evaluated interventions
speciﬁcally designed for recruiters, and of those, only
one reported an improvement in recruitment (although
the data analysis did not adjust for clustering).40 There
is clearly a gap in knowledge with regard to effective
strategies targeting this group, and additional research
aimed at how to increase recruitment by individuals or
sites participating in trials would be beneﬁcial. Other
authors have used multivariable regression to look for
factors that inﬂuence recruitment, although there were
few insights gained from this.2 67 However, this approach
may be worth revisiting as more evaluations of recruit-
ment interventions are published.
Evidence from this review has demonstrated that there
are promising strategies for increasing recruitment to
trials, including telephone reminders to non-responders
and requiring potential participants to opt-out of being
contacted by the trial team. Some of these strategies,
such as open trial designs, need to be considered care-
fully as their use also has disadvantages. Many, however,
require further rigorous evaluation to conclusively deter-
mine their impact.
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